Target intelligence / Profile preview

Neuraminidase (N2) of influenza A virus (N2)

Target
N2
Molecular classification
Enzyme
01

Overview

Neuraminidase (N2) is a tetrameric surface glycoprotein enzyme (EC 3.2.1.18) of influenza A virus, consisting of four ~470-amino-acid monomers with cytoplasmic tail, transmembrane, stalk, and catalytic head domains. It cleaves α-ketosidic linkages of terminal N-acetylneuraminic acid (sialic acid) from glycans, aiding virus entry by clearing respiratory mucins, promoting membrane fusion, and enabling efficient release of progeny virions from host cells by preventing HA-mediated aggregation. The active site features a conserved inner shell of eight residues (e.g., Arg118, Arg152, Glu276, Tyr406 using N2 numbering) for sialic acid binding and catalysis, plus framework residues for structure. N2 belongs to group 2 NA subtypes with specific activity toward α2-3 and α2-6 sialyl linkages, varying by host and isolate. It is a validated antiviral target with inhibitors binding the active site.

Other names
Influenza A virus N2 neuraminidaseN2 neuraminidaseInfluenza neuraminidase subtype N2
02

Mechanism of action

Competitive inhibition of sialic acid cleavage by mimicking transition state of hydrolysis, Binding to active site residues blocking substrate access

03

Biological functions

Cleavage of sialic acid from glycoconjugatesFacilitation of viral release from infected cellsPrevention of viral aggregationPromotion of viral movement through mucins
04

Disease associations

Infection
05

Safety considerations

Development of resistance mutations in active siteAntigenic drift altering inhibitor susceptibility
06

Interacting drugs

Zanamivir

2 more in the full profile.

Beyond the preview

Go deeper on Neuraminidase (N2) of influenza A virus (N2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuraminidase (N2) of influenza A virus (N2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call